Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

The FDA Issued Determination Letter For Mimedx's Request For Designation Noting Axiofill Does Not Meet Regulatory Classification Requirements Of A Human Cell, Tissue, Or Cellular Or Tissue-based Product

Author: Benzinga Newsdesk | March 27, 2024 08:09am

Posted In: MDXG

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist